USPTO Examiner MARTINEZ TARA L - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18734628PREPARATION AND APPLICATION OF SUPRAMOLECULAR SELF-ASSEMBLED HYALURONIC ACID HYDROGELJune 2024December 2025Abandon1811NoNo
18640722IMMUNOREGULATORY MOLECULES AND USES THEREFORApril 2024June 2025Abandon1401NoNo
18621336COMPOSITIONS FOR TREATING MACULAR EDEMAMarch 2024July 2025Abandon1511YesNo
18605381PHARMACEUTICAL PREPARATIONMarch 2024August 2025Allow1820YesNo
18534620ATF5 Peptide Variants and Uses ThereofDecember 2023September 2024Allow1001NoNo
18522766METHODS OF MODULATING ALKNovember 2023January 2025Abandon1401NoNo
18513146METHODS FOR TREATING CANCERNovember 2023January 2025Abandon1410NoNo
18504534COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIANovember 2023December 2024Allow1311NoNo
18503815METHODS FOR TREATING CANCERNovember 2023September 2025Abandon2220NoNo
18496633USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENTOctober 2023September 2024Allow1010NoNo
18461812Methods and Compositions for Treating Vasomotor SymptomsSeptember 2023March 2025Abandon1811NoNo
18455139COMPOUNDS FOR SELECTIVE DISRUPTION OF PROTEIN-PROTEIN INTERACTIONSAugust 2023October 2025Allow2621NoNo
18363416MATERIALS AND METHODS FOR EXTRACELLULAR VESICLE-ASSOCIATED DISEASESAugust 2023January 2025Abandon1801NoNo
18215276METHODS AND COMPOSITIONS FOR IMPROVED COGNITIONJune 2023November 2024Allow1711YesNo
18298933CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USEApril 2023September 2025Abandon2921NoNo
18132517Methods and Compositions for Preventing or Minimizing Epithelial-Mesenchymal TransitionApril 2023August 2024Abandon1611NoNo
18192696MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMSMarch 2023October 2024Abandon1911NoNo
18105293METHODS OF TREATING DISEASE WITH TERLIPRESSINFebruary 2023March 2026Allow3741YesNo
18163155Heparin-Associated Polypeptides and Uses ThereofFebruary 2023March 2024Abandon1401NoNo
18159363NUTRITIONAL FORMULAJanuary 2023January 2025Allow2421YesNo
18063229METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSESDecember 2022August 2025Allow3221YesNo
18070224Micronutrient combination to reduce blood pressureNovember 2022February 2023Allow310YesNo
17994896Micronutrient combination to reduce blood pressureNovember 2022June 2023Allow620YesNo
17969971METHODS OF TREATING INFLAMMATORY SKIN DISORDERSOctober 2022February 2024Abandon1610NoNo
17933276COMPOSITIONS AND METHODS FOR INHIBITING TUMOR-INDUCED IMMUNE SUPPRESSIONSeptember 2022May 2025Abandon3121NoNo
17944998PEPTIDES AND PHARMACEUTICAL, NUTRACEUTICAL OR VETERINARY COMPOSITIONS FOR HAIR LOSS PREVENTION AND/OR TREATMENTSeptember 2022November 2025Allow3820YesNo
17820230NOVEL COMPOUNDS (IMMUNORHELINS)August 2022April 2024Abandon2002YesNo
17889123FIBRONECTIN BASED SCAFFOLD PROTEINSAugust 2022March 2024Abandon1901NoNo
17872552FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINSJuly 2022June 2024Abandon2311NoNo
17861839METHODS FOR TREATING CANCERJuly 2022January 2024Abandon1810NoNo
17861838METHODS FOR TREATING CANCERJuly 2022January 2024Abandon1810NoNo
17852263METHOD FOR PREPARING AMG 416 (ETELCALCETIDE)June 2022April 2024Abandon2111NoNo
17851128ANTITUMOR PEPTIDE AND USE THEREOFJune 2022January 2024Allow1910YesNo
17843676Heparin-Associated Polypeptides and Uses ThereofJune 2022October 2024Abandon2801NoNo
17784007METHOD FOR PREPARING PEPTIDE EMULSION FORMULATIONJune 2022November 2025Abandon4210NoNo
17738362C3 FUSION PROTEIN AND METHODS OF MAKING AND USING THEREOFMay 2022October 2025Abandon4121NoNo
17774093PEPTIDE, COMPOSITION, AND METHOD FOR TREATING, PREVENTING, OR AMELIORATING MOOD DISORDERMay 2022October 2025Abandon4210NoNo
17773323SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACIDApril 2022November 2025Abandon4301NoNo
17705208PEPTIDOMIMETIC-BASED ANTIBODY SURROGATE FOR HER2March 2022July 2024Allow2811YesNo
17697459HEMOSTATIC COMPOSITION AND HEMOSTATIC METHOD USING HEMOSTATIC COMPOSITIONMarch 2022September 2024Allow3020YesNo
17685643PEPTIDE ENCAPSULATING FERRITINMarch 2022December 2025Abandon4511NoNo
17640133Human Recombinant Hyposialylated Erythropoietin, Methods of Purification and Therapeutic Uses ThereofMarch 2022November 2025Allow4411YesNo
17681380METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTSFebruary 2022March 2026Allow4921YesNo
17675336NASAL DELIVERYFebruary 2022November 2023Abandon2010NoNo
17631793METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DAMAGE TO SKINJanuary 2022May 2025Abandon3901NoNo
17630754MODIFIED MULTIMERIC BICYCLIC PEPTIDE LIGANDSJanuary 2022February 2026Abandon4902NoNo
17579563Micronutrient combination to reduce blood pressureJanuary 2022November 2022Allow1021YesNo
17579392NOVEL PROTEINS SPECIFIC FOR CD137January 2022November 2024Allow3421YesNo
17627771METHODS FOR INDUCING FULL ABLATION OF HEMATOPOIESISJanuary 2022February 2026Allow4911YesNo
17627558PREBIOTIC-INDUCED ANTI-TUMOR IMMUNITYJanuary 2022March 2026Abandon5021NoNo
17596099RECOMBINANT 4-1BB BINDING PROTEINS AND THEIR USEDecember 2021June 2025Abandon4301NoNo
17614966PEPTIDES AND USES THEREOFNovember 2021May 2025Abandon4211NoNo
17455831TARGETING DEREGULATED WNT SIGNALING IN CANCER USING STABILIZED ALPHA-HELICES OF BCL-9November 2021September 2025Allow4641NoNo
17531182Ready-To-Use Carfilzomib CompositionsNovember 2021December 2023Abandon2511NoNo
17612089METHODS OF TREATING MUSCULOSKELETAL DEFORMITIES IN QUADRUPED ANIMALSNovember 2021March 2025Abandon4001NoNo
17611660Compositions and Methods for increasing Reproduction Performance in Non Human Mammals Using Recombinant Luteinizing HormoneNovember 2021February 2025Abandon3901NoNo
17519637NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERSNovember 2021October 2023Allow2311YesNo
17605455FLAGELLIN FUSION PROTEIN AND USE THEREOFOctober 2021October 2025Abandon4811NoNo
17502952PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATESOctober 2021May 2024Allow3111NoNo
17491715VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODSOctober 2021December 2023Abandon2611NoNo
17594111NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOFOctober 2021June 2025Abandon4411NoNo
17600198HYPOXIA-INDUCING CRYOGELSSeptember 2021October 2025Abandon4921YesNo
17600221MONOMERIC PEPTIDE MULTI-AGONIST TARGETING THE GLP1 RECEPTOR AND NPY RECEPTORSSeptember 2021April 2025Allow4211YesNo
17440698USE OF EPIDERMAL GROWTH FACTOR IN DIABETIC FOOT ULCER TREATMENTSeptember 2021June 2025Abandon4521NoNo
17476971BI-FUNCTIONAL ARGININE-GLYCINE-ASPARTIC ACID (RGD) PEPTIDES AND METHODS TO PROMOTE ANGIOGENESISSeptember 2021January 2025Abandon4031NoNo
17593286DIRECT REPROGRAMMING OF CARDIAC FIBROBLASTS INTO CARDIOMYOCYTES USING AN ENDOTHELIAL CELL TRANSDIFFERENTIATION STRATEGYSeptember 2021January 2026Abandon5221NoNo
17438806MODULATION OF WNT SIGNALING IN AUDITORY DISORDERSSeptember 2021September 2024Abandon3601NoNo
17470976GLYCOCALYX MIMETIC COATINGSSeptember 2021September 2025Allow4921YesNo
17462185NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOFAugust 2021November 2022Allow1521YesNo
17410743METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSESAugust 2021September 2022Allow1321YesNo
17409642COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASEAugust 2021December 2025Allow5121YesNo
17365530Methods and Compositions for Treating Vasomotor SymptomsJuly 2021September 2023Abandon2711NoNo
17416484FUSION PROTEIN COMPRISING HUMAN LEFTY A PROTEIN VARIANTS AND USE THEREOFJune 2021November 2025Abandon5221NoNo
17351693PHI-4 POLYPEPTIDES AND METHODS FOR THEIR USEJune 2021September 2023Abandon2701NoNo
17347977NUTRITIONAL FORMULAJune 2021October 2022Allow1621YesNo
17348106COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIAJune 2021October 2024Abandon4121NoNo
17344378COLLAGEN REPLACEMENT/REGENERATION FORMULATION AND USES THEREOFJune 2021September 2024Abandon3921NoNo
17299841Erythropoietin Analogs For Veterinary UseJune 2021February 2025Abandon4511YesNo
17294497ACTIVIN/BMP7 CHIMERAS: SUPER-ACTIVE SAB704 AND SAB715, AND THEIR RESPECTIVE NOGGINSENSITIZED VARIANTS, NAB704 AND NAB715; AND NAB204May 2021November 2025Allow5421YesNo
17318706DETECTING AND TREATING CANCERS USING CELL PENETRANT MTP53-OLIGOMERIZATION-DOMAIN PEPTIDEMay 2021January 2025Abandon4421NoNo
17314629NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERSMay 2021October 2023Allow2911NoNo
17246348PHARMACEUTICAL PREPARATIONApril 2021December 2023Allow3111YesNo
17290707TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOFApril 2021October 2025Allow5411YesNo
17290050SELF-ASSEMBLING PEPTIDES AND HYDROGELSApril 2021February 2026Allow5721YesNo
17287398PREPARATION AND APPLICATION OF SUPRAMOLECULAR SELF-ASSEMBLED HYALURONIC ACID HYDROGELApril 2021September 2024Abandon4111NoNo
17233157ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOFApril 2021October 2024Abandon4211NoNo
17227943CANCER TREATMENT METHODS USING NANOFIBER STABILIZED GROWTH FACTORSApril 2021December 2023Allow3221YesNo
17218186COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASESMarch 2021August 2023Abandon2911NoNo
17215738METHODS FOR TREATMENT OF DISEASESMarch 2021June 2024Abandon3921NoNo
17280541MODIFIED HUMAN ERYTHROPOIETINMarch 2021December 2024Allow4521YesNo
17300085Children Blood Transfusion and Thymus Hormonal Therapy as Antiviral and Antibacterial CompoundsMarch 2021September 2023Abandon3101NoNo
17186757FOOD ADDITIVE TO ENHANCE ANIMAL PERFORMANCE AND METHOD OF USING THE SAMEFebruary 2021May 2023Abandon2601NoNo
17183265STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATESFebruary 2021December 2025Abandon5841YesNo
17269788Pharmaceutical Combination Comprising Epidermal Growth Factor and Secretagogue Peptide GHRP6 for the Restoration of Brain DamageFebruary 2021May 2025Abandon5121NoNo
17171841PROTEIN INTERFACESFebruary 2021November 2024Allow4531YesNo
17265158NEUROPROTECTIVE COMPOSITIONS AND USE THEREOFFebruary 2021March 2025Abandon4911NoNo
17124301SERPIN PEPTIDES AND METHODS OF USING THE SAMEDecember 2020December 2024Allow4840YesNo
16953044COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONSNovember 2020June 2023Abandon3111NoNo
16951529COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIANovember 2020August 2023Allow3211YesNo
16949817NON-RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN CONCENTRATENovember 2020August 2024Allow4531YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARTINEZ, TARA L.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
1
(33.3%)
Examiner Reversed
2
(66.7%)
Reversal Percentile
85.6%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
26
Allowed After Appeal Filing
7
(26.9%)
Not Allowed After Appeal Filing
19
(73.1%)
Filing Benefit Percentile
39.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MARTINEZ, TARA L - Prosecution Strategy Guide

Executive Summary

Examiner MARTINEZ, TARA L works in Art Unit 1654 and has examined 362 patent applications in our dataset. With an allowance rate of 62.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner MARTINEZ, TARA L's allowance rate of 62.4% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MARTINEZ, TARA L receive 2.44 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MARTINEZ, TARA L is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +62.5% benefit to allowance rate for applications examined by MARTINEZ, TARA L. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.7% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 39.9% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.4% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.